News

Life Sciences

Galera Therapeutics Secures $150 Million Series C for Oral Mucositis in Cancer Patients

Edward Kim | Equities.com |

Equity + royalty financing for Phase 3 trial of lead product candidate in Q4 2018 (Image: Galera Therapeutics).


Braeburn Shows Positive Top-Line Phase 3 Data in Chronic Low Back Pain

Edward Kim | Equities.com |

Weekly and monthly buprenorphine for patients previously on long-term daily opioid therapy (Image: Braeburn)


Y-mAbs Therapeutics' $80 Million IPO Expected This Week for Pediatric Cancer

Edward Kim | Equities.com |

Two Phase 2 Breakthrough Therapy candidates licensed from Memorial Sloan Kettering (Image: Y-mAbs Therapeutics).


Boehringer Ingelheim Acquires ViraTherapeutics and its Oncolytic Virus Program for $245 Million

Edward Kim | Equities.com |

Third major acquisition of an oncolytic virus company by Big Pharma this year (Image: UCLA Jonsson Comprehensive Cancer Center).


Principia Biopharma's $75 Million IPO Expected This Week for Small Molecule Drug Discovery

Edward Kim | Equities.com |

Novel drug discovery platform with programs in immunology, central nervous system disorders and oncology (Image: Principia Biopharma).


Merck KGaA and Pfizer Show that Phase 3 Combination Therapy Delays Progression of Kidney Cancer

Edward Kim | Equities.com |

Bavencio (avelumab) + Inlyta (axitinib) show statistically significant improvement in progression-free survival vs Sutent (sunitinib) (Image: prIME Oncology).


Kodiak Sciences Files $100 Million IPO for Chronic Retinal Diseases

Edward Kim | Equities.com |

Lead candidate targeting wet age-related macular degeneration and diabetic retinopathy.


Twentyeight-Seven Therapeutics Launches with $65 Million for Cancer Tumor Suppression

Edward Kim | Equities.com |

Modulating expression of oncogenes and other disease-causing proteins (Image: Twentyeight-Seven Therapeutics)


Exonics Therapeutics Shows Restoral of Dystrophin Expression in Canine Model of Duchenne Muscular Dystrophy

Edward Kim | Equities.com |

First study of Exonics’ gene editing technology in large mammals supports clinical advancement (Image: Exonics Therapeutics).


Fulcrum Therapeutics Raises $80 Million Series B Round for Facioscapulohumeral Muscular Dystrophy (FSHD)

Edward Kim | Equities.com |

Small molecule, precision medicine approach to address serious diseases of gene misregulation (Image: Fulcrum Therapeutics).


Emerging Growth

Viking Energy Group Inc

Viking Energy Group Inc is the United States based independent exploration and production company. The company is engaged in the acquisition, exploration, development, and production of oil and natural gas…

Events

Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more